XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Segments
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Segments Segments
The Company's CODM assesses the operating performance of and allocates resources for several operating segments using Segment Adjusted EBITDA as a basis. Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underlying business performance of an individual enterprise. The Company defines Segment Adjusted EBITDA as net income (loss) before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on settlement agreements where noncash consideration is paid, (vi) adjustments for accrued bonuses paid in equity awards, (vii) gain or loss on disposals of assets, (viii) loss on impairment of goodwill and other noncurrent assets, (ix) equity in net income loss of affiliates, and (x) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates, but includes proceeds from the sale of assets in the period sold.
Because the Company uses Segment Adjusted EBITDA as its primary measure of segment performance, it has included this measure in its discussion of segment operating results. The Company has also disclosed revenues from external customers and intersegment revenues for each reportable segment. The CODM does not use total assets by segment to evaluate segment performance or allocate resources, and accordingly, these amounts are not required to be disclosed. The Company's segment presentation excludes amounts related to the operations of Trans Ova prior to its sale, which are reported as discontinued operations (Note 3).
For the three and nine months ended September 30, 2023, the Company's reportable segments were (i) Biopharmaceuticals and (ii) Exemplar. These identified reportable segments met the quantitative thresholds to be reported separately for the nine months ended September 30, 2023. See Note 2 for a description of Biopharmaceuticals. See Note 1 for a description of Exemplar.
Segment Adjusted EBITDA by reportable segment was as follows:
Three Months Ended 
 September 30,		Nine Months Ended 
 September 30,
2023202220232022
Biopharmaceuticals
$(17,068)$(18,082)$(56,345)$(58,956)
Exemplar(464)346 (426)4,699 
Segment Adjusted EBITDA for reportable segments$(17,532)$(17,736)$(56,771)$(54,257)

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:
Three Months Ended 
 September 30,		Nine Months Ended 
 September 30,
2023202220232022
Segment Adjusted EBITDA for reportable segments$(17,532)$(17,736)$(56,771)$(54,257)
All Other Segment Adjusted EBITDA— — — — 
Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates236 674 491 1,342 
Interest Income856 56 2,317 131 
Add recognition of previously deferred revenue associated with upfront and milestone payments— 14,561 — 14,561 
Other expenses:
Interest expense(1)(2,036)(461)(6,137)
Depreciation and amortization(1,650)(1,717)(5,054)(5,470)
Gain (loss) on disposals of assets28 — 68 — 
Impairment losses— — — (1,120)
Stock-based compensation expense(2,306)(2,184)(7,626)(7,987)
Adjustment related to accrued bonuses paid in equity awards— — 3,361 1,698 
Equity in net income (loss) of affiliates
— 862 — 861 
Other— — — (105)
Shares issue for payment of services— — (545)(576)
Corporate noncash items568 (168)1,246 (636)
Eliminations— (6)— (103)
Consolidated net loss from continuing operations before income taxes$(19,801)$(7,694)$(62,974)$(57,798)
Revenues by reportable segment were as follows:
Three Months Ended September 30, 2023
Biopharmaceuticals
ExemplarTotal
Revenues from external customers / Total segment revenues
$— $1,379 $1,379 
Three Months Ended September 30, 2022
Biopharmaceuticals
ExemplarTotal
Revenues from external customers / Total segment revenues
$14,624 $2,098 $16,722 
Nine Months Ended September 30, 2023
Biopharmaceuticals
ExemplarTotal
Revenues from external customers / Total segment revenues
$— $4,997 $4,997 
Nine Months Ended September 30, 2022
Biopharmaceuticals
ExemplarTotal
Revenues from external customers / Total segment revenues
$14,778 $10,368 $25,146 
Total segment revenues from reportable segments equal total consolidated revenues on the condensed consolidated statements of operations.
For the three months ended September 30, 2023 and 2022, 78.7% and 41.1%, respectively, of total consolidated revenue was attributable to four customers in 2023 and one customer in 2022 in the Exemplar segment. For the nine months ended September 30, 2023 and 2022, 78.2% and 62.4%, respectively, of total consolidated revenue was attributable to four customers in 2023 and one customer in 2022 in the Exemplar segment.
As of September 30, 2023 and December 31, 2022, the Company had $1,908 and $2,591, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $0 and $63 for the three months ended September 30, 2023 and 2022, respectively, and $0 and $217 for the nine months ended September 30, 2023 and 2022, respectively.